Quick Takeaways:
- VETmAb Biosciences reported positive proof-of-concept results for VMB-C001a, a long-acting anti-IL-23 monoclonal antibody for canine chronic inflammatory enteropathy (CIE), or IBD. Treatment success reached 77.8% versus 30% with placebo.
- In the 19-dog pilot study, 11.1% of treated dogs achieved remission, while 66.7% showed a partial response. The therapy appeared well tolerated and received eligibility for the FDA’s expanded conditional approval pathway.
- VETmAb BIO plans to advance VMB-C001a toward pivotal development. Its five-program pipeline also includes feline CIE, immune-mediated diseases and canine metabolic disease. The founding team previously built Kindred Biosciences, acquired by Elanco for $444 million.
Why It Matters?
VETmAb’s positive proof-of-concept results position VMB-C001a as a potential biologic option for canine chronic inflammatory enteropathy, an area with unmet treatment needs. The 77.8% treatment success rate and eligibility for the FDA’s expanded conditional approval pathway support further development, but the small 19-dog study requires validation in larger trials before efficacy and market potential can be established.
Source: Globenewswire
